This study is looking at defibrotide, a drug given through an IV, to see if it is safe and works for people with severe COVID-19 pneumonia. Researchers want to understand if this drug can help patients who are hospitalized and need oxygen. You might be able to join if you are 18 to 100 years old, have confirmed COVID-19, and have lung problems seen on X-rays. The study is currently unclear on its recruitment status and plans to enroll 42 participants. The main goal is to check for side effects like bleeding and low blood pressure for up to 21 days.

Study design

This is a Phase 2 pilot study, meaning it's an early look at the drug's safety and effectiveness. It's a single-arm study, so all 42 participants will receive defibrotide.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Your safety will be monitored for up to 21 days after treatment to check for specific side effects.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.